Table 3.
Quality of Evidence |
Low | Moderate | Moderate | Low | Low | Moderate | Low | Very Low |
---|---|---|---|---|---|---|---|---|
Dose effect | NA | NA | NA | NA | NA | NA | NA | NA |
Effect size | Moderate | Moderate | Moderate | Small | Small | Moderate | NA | Small |
Publication bias | √ | √ | √ | √ | √ | √ | √ | √ |
Imprecision | √ | √ | √ | √ | √ | √ | √ | √ |
Indirectness | √ | √ | √ | √ | √ | √ | √ | √ |
Inconsistency | √ | √ | √ | √ | √ | √ | √ | √ |
Risk of bias | × | √ | √ | √ | √ | √ | √ | × |
Study design | Cases | Retrospective | Retrospective | Retrospective | Non-randomized clinical trial | Non-randomized clinical trial | Non-randomized clinical trial | Retrospective |
Study | Peterson et al. 2020 [25] | Ronsley et al. 2021 [32] | Selt et al. 2020 [33] | Toledano et al. 2021 [34] | McCowage et al. 2018 [35] | Manoharan et al. 2020 [36] | Geoerger et al. 2018 [37] | Paul et al. 2020 [38] |
√ indicates no serious limitations; ×, serious limitations; effect size—objective response rate (ORR) ≥ 0.5 for moderate effect or ORR ≥ 0.8 for large effect; NA, not applicable.